SLU-PP-332 vs Tirzepatide
Side-by-side comparison of SLU-PP-332 and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
SLU-PP-332
Tirzepatide
SLU-PP-332
SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023…
Lowest listed price: $69.99 across 5 listings
Full SLU-PP-332 profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | SLU-PP-332 | Tirzepatide |
|---|---|---|
| Category | Performance | Metabolic & Weight Loss |
| Research Stage | Preclinical | FDA Approved |
| Mechanism of Action | SLU-PP-332 acts through pan-agonism of the three estrogen-related receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3), a subfamily of orphan nuclear receptors that regulate oxidative metabolism, mitochondrial biogenesis, and exercise-responsive gene expression. The… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | — | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | Research compound — no established human doses. Animal studies: 10-50 mg/kg | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | — | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | The side effect profile of SLU-PP-332 in humans is undocumented because no clinical trials have been conducted. Rodent studies report generally acceptable tolerability at doses producing exercise-mimetic metabolic effects, without overt signs of toxicity on… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 290.3 g/mol | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price History
3 data points- Half Nattys
- Ion Peptide
- BHG Labs
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
SLU-PP-332: potential benefits
- Exercise mimicry without physical exertion
- Enhanced fat oxidation
- Increased mitochondrial biogenesis
- Improved endurance capacity
- Muscle fiber type conversion
- Metabolic health improvement
Tirzepatide: potential benefits
- Mean body weight reduction of 20.9% at 72 weeks on 15 mg for everyone randomized (treatment-regimen estimand), 22.5% in the efficacy estimand (SURMOUNT-1, PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between SLU-PP-332 and Tirzepatide?
SLU-PP-332 is a performance that slu-pp-332 acts through pan-agonism of the three estrogen-related receptors (errα/nr3b1, errβ/nr3b2, errγ/nr3b3), a subfamily of orphan nuclear receptors that regulate oxidative…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (not reported vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, SLU-PP-332 or Tirzepatide?
SLU-PP-332 has a half-life of not reported. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, SLU-PP-332 or Tirzepatide?
Lowest listed price on BodyHackGuide: SLU-PP-332 from $69.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack SLU-PP-332 and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. SLU-PP-332 and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy SLU-PP-332 or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.